Skip to main content

Trillium Therapeutics Inc. (TRIL)

NASDAQ: TRIL · IEX Real-Time Price · USD
17.91 0.05 (0.28%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap1.89B
Revenue (ttm)43,000
Net Income (ttm)33.87M
Shares Out103.78M
EPS (ttm)-0.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume655,310
Open17.87
Previous Close17.86
Day's Range17.80 - 17.94
52-Week Range5.80 - 20.96
Beta1.98
AnalystsStrong Buy
Price Target20.26 (+13.1%)
Est. Earnings DateNov 15, 2021

About TRIL

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company ...

IndustryBiotechnology
Founded2004
Employees33
Stock ExchangeNASDAQ
Ticker SymbolTRIL
Full Company Profile

Financial Performance

In 2020, TRIL's revenue was 148,000, an increase of 19.35% compared to the previous year's 124,000. Losses were -59.35 million, 55.8% more than in 2019.

Financial numbers in millions CADFinancial Statements

Analyst Forecast

According to 7 analysts, the average rating for TRIL stock is "Strong Buy." The 12-month stock price forecast is 20.26, which is an increase of 13.11% from the latest price.

Price Target
$20.26
(13.11% upside)
Analyst Consensus: Strong Buy

News

New Strong Sell Stocks for September 15th

ARCE, NSSC, PAGP, TRIL, and VALE have been added to the Zacks Rank #5 (Strong Sell) List on September 15, 2021.

Other symbols:ARCENSSCPAGPVALE
1 month ago - Zacks Investment Research

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRIL

NEW YORK, Sept. 11, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Actio...

1 month ago - PRNewsWire

Why Investors Should Love Pfizer's Acquisition of Trillium

This deal checks off several boxes for Pfizer.

Other symbols:PFE
1 month ago - The Motley Fool

Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs

Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.

Other symbols:BIBJNJLABUMRNAPFE
1 month ago - Zacks Investment Research

Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion

Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.

Other symbols:PFE
1 month ago - Zacks Investment Research

Trillium Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Trilliu...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Trillium Therapeutics Inc. (NASDAQ: TRIL) to Pfizer Inc. for $18.50 per share in cash...

1 month ago - Business Wire

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Other symbols:BBCCNCRIBBJPFESBIOXBI
1 month ago - Zacks Investment Research

Pfizer To Buy Cancer Biotech Company Trillium For $2.3 Million

What do you do when you're brimming with billions of dollars in new vaccine revenue? You splurge, of course!

Other symbols:PFE
1 month ago - The Motley Fool

What Did the Stock Market Do Today, Aug. 23? 3 Big Stories to Catch Up On.

So what did the stock market do today? Investors cheered on Pfizer stock and rallied behind infrastructure plays.

1 month ago - InvestorPlace

Dual Wins for Pfizer Mean Big Jumps for These 2 Stocks

The drugmaker's own stock is up 3% Monday morning, but that's nothing compared to the impact it's having on a couple of other healthcare companies.

Other symbols:BNTX
1 month ago - The Motley Fool

TRIL Stock: The Huge $2.3B Deal Sending Trillium Therapeutics Up 200%

TRIL stock is soaring to nearly triple its Friday prices. Pfizer is acquiring the oncology company in a multi-billion dollar deal.

1 month ago - InvestorPlace

Pfizer to buy cancer drug maker Trillium for $2.3B

Pfizer said it will pay $18.50 a share for the Cambridge, Massachusetts-based drug maker Trillium.

Other symbols:PFE
1 month ago - New York Post

Why Trillium Therapeutics Stock Is Skyrocketing Today

Pfizer may have gotten a fantastic deal on this clinical-stage oncology company.

1 month ago - The Motley Fool

Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

Pfizer Inc (NYSE: PFE) has agreed to acquire Trillium Therapeutics Inc (NASDAQ: TRIL) for $18.50 per share, equivalent to an implied equity value of $2.26 billion. The offer price represents a 118% prem...

Other symbols:PFE
1 month ago - Benzinga

Trillium Therapeutics shares soar on Pfizer's $2.26B deal

Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.

Other symbols:PFE
1 month ago - Fox Business

Pfizer to buy Trillium Therapeutics in $2.26 billion deal

Pfizer Inc said on Monday it would buy shares of Trillium Therapeutics Inc that it does not already own in a deal that values the cancer drugs maker at $2.26 billion.

Other symbols:PFE
1 month ago - Reuters

Pfizer to Acquire Trillium Therapeutics Inc.

Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies

1 month ago - GlobeNewsWire

Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results

CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, t...

2 months ago - GlobeNewsWire

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidin...

CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, t...

2 months ago - GlobeNewsWire

$5,000 Invested in These 3 Healthcare Stocks Could Make You Rich Over the Next 10 Years

These companies could upend the industry in the years ahead.

Other symbols:PACBTDOC
2 months ago - The Motley Fool

This Biotech Stock Is Too Cheap to Ignore

Wall Street's short attention span has created an attractive entry point in this once-loved biotech.

2 months ago - The Motley Fool

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidin...

CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, t...

3 months ago - GlobeNewsWire

Trillium Therapeutics Joins Russell 2000® and 3000® Indices

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies ...

3 months ago - GlobeNewsWire

Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the tr...

4 months ago - GlobeNewsWire

Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, to...

5 months ago - GlobeNewsWire